AU2019379167A1 - Method of improving prediction of response for cancer patients treated with immunotherapy - Google Patents

Method of improving prediction of response for cancer patients treated with immunotherapy Download PDF

Info

Publication number
AU2019379167A1
AU2019379167A1 AU2019379167A AU2019379167A AU2019379167A1 AU 2019379167 A1 AU2019379167 A1 AU 2019379167A1 AU 2019379167 A AU2019379167 A AU 2019379167A AU 2019379167 A AU2019379167 A AU 2019379167A AU 2019379167 A1 AU2019379167 A1 AU 2019379167A1
Authority
AU
Australia
Prior art keywords
loh
cancer
sample
tumor
tmb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019379167A
Other languages
English (en)
Inventor
Gustavo CERQUEIRA
Nicholas C. Dracopoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Personal Genome Diagnostics Inc
Original Assignee
Personal Genome Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Personal Genome Diagnostics Inc filed Critical Personal Genome Diagnostics Inc
Publication of AU2019379167A1 publication Critical patent/AU2019379167A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019379167A 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy Pending AU2019379167A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862767979P 2018-11-15 2018-11-15
US62/767,979 2018-11-15
PCT/US2019/061710 WO2020102674A1 (en) 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy

Publications (1)

Publication Number Publication Date
AU2019379167A1 true AU2019379167A1 (en) 2021-06-03

Family

ID=70727341

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019379167A Pending AU2019379167A1 (en) 2018-11-15 2019-11-15 Method of improving prediction of response for cancer patients treated with immunotherapy

Country Status (6)

Country Link
US (2) US12497661B2 (https=)
EP (1) EP3880246A4 (https=)
JP (2) JP7623281B2 (https=)
AU (1) AU2019379167A1 (https=)
CA (1) CA3120200A1 (https=)
WO (1) WO2020102674A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230056761A (ko) * 2020-08-26 2023-04-27 리제너론 파마슈티칼스 인코포레이티드 Pd-1 저해제의 투여에 의한 암 치료 방법
CN111979323A (zh) * 2020-08-28 2020-11-24 深圳裕策生物科技有限公司 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统
CN112029861B (zh) * 2020-09-07 2021-09-21 臻悦生物科技江苏有限公司 基于捕获测序技术的肿瘤突变负荷检测装置及方法
WO2022232503A1 (en) * 2021-04-30 2022-11-03 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2023196390A1 (en) * 2022-04-06 2023-10-12 Foundation Medicine, Inc. Aneuploidy biomarkers associated with response to anti-cancer therapies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531279B1 (en) * 1998-04-15 2003-03-11 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (FLAP), polymorphic markers thereof and methods for detection of asthma
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
EP3012329B1 (en) * 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
KR20230030022A (ko) * 2014-11-13 2023-03-03 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
CN117467603A (zh) 2015-04-27 2024-01-30 癌症研究技术有限公司 治疗癌症的方法
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
CA3015913A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
CN114959918A (zh) * 2016-02-29 2022-08-30 基础医疗股份有限公司 用于评估肿瘤突变负荷的方法和系统
JP6821693B2 (ja) * 2016-02-29 2021-01-27 ジェネンテック， インコーポレイテッド がんのための治療方法及び診断方法
US20190247435A1 (en) 2016-06-29 2019-08-15 The Johns Hopkins University Neoantigens as targets for immunotherapy
EP3516081A4 (en) 2016-09-23 2020-07-29 Memorial Sloan Kettering Cancer Center DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY
WO2018071796A2 (en) 2016-10-13 2018-04-19 The Johns Hopkins University Compositions and methods for identifying functional anti-tumor t cell responses
US11634777B2 (en) * 2017-01-13 2023-04-25 The General Hospital Corporation Resistance to checkpoint blockade therapy
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
CN117987553A (zh) * 2017-09-25 2024-05-07 纪念斯隆凯特琳癌症中心 肿瘤突变负荷和检查点免疫疗法

Also Published As

Publication number Publication date
WO2020102674A1 (en) 2020-05-22
US20200157642A1 (en) 2020-05-21
JP2022513068A (ja) 2022-02-07
EP3880246A4 (en) 2022-08-10
EP3880246A1 (en) 2021-09-22
JP7623281B2 (ja) 2025-01-28
CA3120200A1 (en) 2020-05-22
US12497661B2 (en) 2025-12-16
JP2025000809A (ja) 2025-01-07
US20260071282A1 (en) 2026-03-12

Similar Documents

Publication Publication Date Title
US20260071282A1 (en) Method of improving prediction of response for cancer patients treated with immunotherapy
Dushyanthen et al. Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer
Liu et al. Mechanisms of resistance to immune checkpoint blockade
Biran et al. The genetics of alopecia areata: new approaches, new findings, new treatments
Ahn et al. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression
Klaver et al. Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
US20210388438A1 (en) Method for selecting neoepitopes
Di Sante et al. Collagen specific T-cell repertoire and HLA-DR alleles: biomarkers of active refractory rheumatoid arthritis
Frijlink et al. PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice
WO2020221783A1 (en) Methods for pre-selection of neoepitopes
Malheiros et al. Genome‐wide gene expression profiling reveals unsuspected molecular alterations in pemphigus foliaceus
JP2025019066A (ja) 癌の免疫療法のための複合バイオマーカー
López‐Villalobos et al. Association of CD 28 and CTLA 4 haplotypes with susceptibility to primary Sjögren′ s syndrome in Mexican population
Gong et al. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy
Wang et al. The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma
Dahl et al. The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018
Hou et al. Rational discovery of response biomarkers: candidate prognostic factors and biomarkers for checkpoint inhibitor-based immunotherapy
Zhong et al. The necessary role of an efficient tumor immunotherapy by MHC II expression on amateur APCs
JP7626777B2 (ja) マイクロサテライト不安定性シグネチャー
Rosaria Noviello et al. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial
Goli et al. Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy
Yan et al. Causal Impact of Immune Phenotypes on Herpes Zoster and Postherpetic Neuralgia: Insights from Mendelian Randomization Analysis
Soria et al. IL-6 and IL-27 negatively regulate CRTAM-expressing CD4+ T-cells associated with lymphoid-driven synovitis
Wang et al. Comprehensive Analysis of the Immune Microenvironment Reveals that CD52 is a Marker for Breast Cancer Treatment with Immune Checkpoint Inhibitors
Rawal et al. Major Histocompatibility Complex Dmα/β Genes and Their Expressional Diversity in Healthy and Diseased Water Buffalo Bubalus bubalis